Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies
- 15 April 2020
- journal article
- review article
- Published by Elsevier BV in Gene
- Vol. 734, 144391
- https://doi.org/10.1016/j.gene.2020.144391
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- An Updated Meta-Analysis on the Association of MDM2 SNP309 Polymorphism with Colorectal Cancer RiskPLOS ONE, 2013
- Colorectal Cancer: Molecular Mutations and PolymorphismsFrontiers in Oncology, 2013
- Molecular Basis of Colorectal CancerNew England Journal of Medicine, 2009
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization StudiesAmerican Journal of Epidemiology, 2009
- Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genesInternational Journal of Colorectal Disease, 2007
- Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patientsBreast Cancer Research, 2007
- Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cellsJournal of Medical Genetics, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986